These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 20562776)

  • 1. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized antipsychotic treatment: the adverse effects perspectives.
    Plesnicar BK
    Psychiatr Danub; 2010 Jun; 22(2):329-34. PubMed ID: 20562775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
    van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Saito M; Yasui-Furukori N; Kaneko S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of antipsychoatics.
    Ozaki N
    Nagoya J Med Sci; 2004 May; 67(1-2):1-7. PubMed ID: 15279062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of antipsychotics: useful for the clinician?
    Bondy B; Spellmann I
    Curr Opin Psychiatry; 2007 Mar; 20(2):126-30. PubMed ID: 17278909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
    Zhang JP; Malhotra AK
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacogenetics in the treatment of schizophrenia].
    Furukori N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):65-9. PubMed ID: 20491279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics can improve antipsychotic treatment in schizophrenia.
    Xu Q; Wu X; Xiong Y; Xing Q; He L; Qin S
    Front Med; 2013 Jun; 7(2):180-90. PubMed ID: 23606027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].
    Suzuki Y; Sawamura H; Someya T
    Seishin Shinkeigaku Zasshi; 2006; 108(6):633-41. PubMed ID: 16910543
    [No Abstract]   [Full Text] [Related]  

  • 14. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments.
    Arranz MJ; Gonzalez-Rodriguez A; Perez-Blanco J; Penadés R; Gutierrez B; Ibañez L; Arias B; Brunet M; Cervilla J; Salazar J; Catalan R
    Transl Psychiatry; 2019 Jul; 9(1):177. PubMed ID: 31346157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
    Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
    Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
    Ingelman-Sundberg M; Sim SC
    Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.
    Ravyn D; Ravyn V; Lowney R; Nasrallah HA
    Schizophr Res; 2013 Sep; 149(1-3):1-14. PubMed ID: 23870808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics as a tool in the therapy of schizophrenia.
    Wilffert B; Zaal R; Brouwers JR
    Pharm World Sci; 2005 Feb; 27(1):20-30. PubMed ID: 15861931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.